AIM IMMUNOTECH INC. Interest Expense, Debt, Excluding Amortization
AIM IMMUNOTECH INC. (AIM) reported Interest Expense, Debt, Excluding Amortization of $149.00 thousand for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseDebtExcludingAmortization · last filed 2025-08-14
- AIM IMMUNOTECH INC. interest expense, debt, excluding amortization for the quarter ending 2025-06-30 was $149.00K, a 43.27% increase year-over-year.
- AIM IMMUNOTECH INC. interest expense, debt, excluding amortization for the quarter ending 2025-03-31 was $124.00K, a 327.59% increase year-over-year.
- AIM IMMUNOTECH INC. interest expense, debt, excluding amortization for the quarter ending 2024-12-31 was $66.00K.
- AIM IMMUNOTECH INC. interest expense, debt, excluding amortization for the quarter ending 2024-09-30 was $93.00K.
- AIM IMMUNOTECH INC. interest expense, debt, excluding amortization for fiscal 2024 was $292.00K.
| Period end | Interest Expense, Debt, Excluding Amortization 3 month | Interest Expense, Debt, Excluding Amortization 6 month | Interest Expense, Debt, Excluding Amortization 9 month | Interest Expense, Debt, Excluding Amortization 12 month |
|---|---|---|---|---|
| 2025-06-30 | $149.00K 10-Q · filed 2025-08-14 | $273.00K 10-Q · filed 2025-08-14 | $339.00K derived: sum of 3 quarters · filed 2025-08-14 | $432.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | $124.00K 10-Q · filed 2025-05-15 | $190.00K derived: sum of 2 quarters · filed 2025-05-15 | $283.00K derived: sum of 3 quarters · filed 2025-05-15 | $387.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-12-31 | $66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $159.00K derived: sum of 2 quarters · filed 2025-03-27 | $263.00K derived: sum of 3 quarters · filed 2025-03-27 | $292.00K 10-K · filed 2025-03-27 |
| 2024-09-30 | $93.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $197.00K derived: sum of 2 quarters · filed 2024-11-14 | $226.00K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $104.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $133.00K 10-Q · filed 2024-08-14 | ||
| 2024-03-31 | $29.00K 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |